Following FDA win, Portola loses CEO William Lis
Just one month after Portola won a long-awaited FDA approval of its bleeding antidote for blood thinners, the company’s chief executive is relinquishing the reins to retire.
CEO William Lis, who’s been leading the company since 2008, will stay on until August 1, then exit both the company and the board. Portola $PTLA has appointed the company’s EVP of R&D John Curnutte and CFO Mardi Dier as interim co-presidents, along with their current positions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.